PTC Therapeutics, Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has maintained its negative opinion on the renewal ...
EMA re-confirms non-renewal of conditional marketing authorisation of Duchenne muscular dystrophy medicine, Translarna: Amsterdam, The Netherlands Monday, October 21, 2024, 10:00 ...
The agency has reconfirmed its recommendation to not give positive opinion to Translarna (ataluren) after a reexamination of the available data.
Seaport Therapeutics Inc. has followed up its recent fundraiser with an oversubscribed $225 million series B financing that will help set it on the path to a phase IIb study of major depressive ...
The drug's active substance, ataluren, helps cells bypass the mutation to produce functional dystrophin protein. Following ...
NICE's HST committee has three more technology evaluations underway already, including ataluren for Duchenne Muscular Dystrophy. The first drug approved through the HST process was Alexion's ...
Zacks.com on MSN14d
PTCT Stock Rises on Positive Updates on Friedreich Ataxia ProgramPTCT announced positive results on two different long-term extension studies on vatiquinone.The company also announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback